Multikinase Tki Toxicity Profile

Multikinase TKI Toxicity Profile

Strategies for Managing VEGF-TKI Toxicities

Targeted Oncology

FGFR-Specific TKIs Versus Multikinase Inhibitors

Targeted Oncology

Toxicity Management of TKI Melissa Viatori, M.D., PhD.

TKI Therapy: Impact of Age and Adverse Events

Targeted Oncology

Novel drug toxicities in immunotherapy, TKIs and CAR-T

Role of the Multikinase Inhibitor Regorafenib in Metastatic Colorectal Cancer

The Role of Multikinase TKIs for NSCLC

Favorable Safety Profile in Novel TRK Inhibitor

Targeted Treatment in NTRK Fusion-Positive Cancer

Targeted Oncology

iCell Cardiomyocytes as a Tool to Decipher Kinase Inhibitor Linked Toxicities

Fujifilm Cellular Dynamics

Selecting Frontline Multikinase Inhibition in HCC

CSF1 Inhibition in TSGCT: Managing Adverse Events

Introduction to EGFR inhibitors

LUNGevityFoundation

Dr. Grigg on Frontline Tyrosine Kinase Inhibitors in RCC

Tyrosine Kinase Inhibitors (TKIs) - Imatinib (Gleevec) - Pharmacology - CML and ALL

Medicosis Perfectionalis

Management of Adverse Events for ALK-Targeted TKIs

Targeted Oncology

TKIs to treat EGFRm-positive NSCLC

Case 3: Selecting Between TKI Inhibitors

Targeted Oncology

Poor-Risk Advanced RCC: TKI Therapy & Outlook

Targeted Oncology